Failure of monoclonal antibodies against CGRP or its receptor does not imply lack of efficacy of other drugs from the same class
Saved in:
| Published in: | Neurología (Barcelona, English ed. ) Vol. 36; no. 8; pp. 638 - 640 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Elsevier España, S.L.U
01.10.2021
Elsevier España |
| Subjects: | |
| ISSN: | 2173-5808, 2173-5808 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Author | González-García, N. Porta-Etessam, J. Guerrero, Á.L. García-Azorín, D. |
|---|---|
| Author_xml | – sequence: 1 givenname: J. surname: Porta-Etessam fullname: Porta-Etessam, J. email: jporta@yahoo.com organization: Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario San Carlos, Madrid, Spain – sequence: 2 givenname: N. surname: González-García fullname: González-García, N. organization: Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario San Carlos, Madrid, Spain – sequence: 3 givenname: Á.L. surname: Guerrero fullname: Guerrero, Á.L. organization: Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain – sequence: 4 givenname: D. surname: García-Azorín fullname: García-Azorín, D. organization: Unidad de Cefaleas, Servicio de Neurología, Hospital Clínico Universitario de Valladolid, Valladolid, Spain |
| BookMark | eNqVUk2LFDEQbWQF13X_gYccvcyYdHe60yKCDO66sKD4cQ5JdWXMbDoZk7QwN3-6aVtBBFnMJVXFq5dUvfe4OvPBY1U9ZXTLKOueH7Y-OvT7bU3rpbSlVDyozmvWNxsuqDj7I35UXaZ0oOV0nAlan1ffr5R1c0QSDJmCD-CCV44on60Oo8VE1F5ZnzLZXX94T0IkNicSEfCYSzKGgvAhEzsd3Yk4BXcLExpjQcFpiUP-ggUY530iJoaJlJwkNSEBp1J6Uj00yiW8_HVfVJ-v3nzavd3cvru-2b2-3UBLW7GBXuHQCEQDzAxGN9AZ05eRDNPA2pHzrteAiJwb7HjHUDeCjSODtgM2dM1FdbPyjkEd5DHaScWTDMrKn4UQ91LFbMGhZMgbpEJTXYt2gHEApqnRrRlQaTPQwvVs5TrG8HXGlOVkE6BzymOYk6w5p13dCL5AX6xQiCGliEaCzSrb4HMsm5eMykVFeZCrinJRcakWFUtz-1fz73_f0_ZqbcOyz28Wo0xg0QOOtgiXy8D2fwnAWV8UdXd4wnQIcywmSZLJVEsqPy7-WuxVs-KsoW8Kwct_E9z__g-xc-Ye |
| CitedBy_id | crossref_primary_10_1186_s10194_024_01764_9 crossref_primary_10_1186_s10194_022_01415_x crossref_primary_10_3389_fneur_2023_1154420 crossref_primary_10_2169_internalmedicine_4360_24 crossref_primary_10_1136_ejhpharm_2021_002946 crossref_primary_10_1136_ejhpharm_2023_003779 |
| Cites_doi | 10.1016/S0140-6736(19)32504-8 10.1186/s10194-017-0807-1 10.1016/S0140-6736(19)31946-4 10.1111/head.13729 10.1016/S1474-4422(17)30083-2 10.1016/S1474-4422(16)00019-3 10.1177/0333102418759786 10.1016/j.peptides.2019.04.012 10.1056/NEJMoa1705848 10.1016/S1474-4422(20)30279-9 |
| ContentType | Journal Article |
| Copyright | 2020 Sociedad Española de Neurología Sociedad Española de Neurología |
| Copyright_xml | – notice: 2020 Sociedad Española de Neurología – notice: Sociedad Española de Neurología |
| DBID | 6I. AAFTH AAYXX CITATION 7X8 DOA |
| DOI | 10.1016/j.nrleng.2020.10.008 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | El fracaso a anticuerpos monoclonales frente a CGRP o su receptor no implica la inefectividad a otros fármacos de la misma clase terapéutica |
| EISSN | 2173-5808 |
| EndPage | 640 |
| ExternalDocumentID | oai_doaj_org_article_1e53e08b0b2849cd9c1b0fb4f9eabf90 10_1016_j_nrleng_2020_10_008 S2173580821000973 1_s2_0_S2173580821000973 |
| Genre | Correspondence |
| GroupedDBID | --K .1- .FO .~1 0R~ 1P~ 1~. 1~5 4.4 457 4G. 65R 7-5 8P~ AAEDW AAIKJ AALRI AAXUO AAYWO ABBQC ABCQJ ABMAC ABTEW ABWVN ACGFS ACRPL ACVFH ADBBV ADCNI ADEZE ADNMO ADVLN AEKER AEUPX AEVXI AFPUW AFRHN AFTJW AGHFR AGWIK AGYEJ AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BCNDV BLXMC EBS EFLBG EJD FDB FEDTE FIRID FNPLU GBLVA GROUPED_DOAJ HVGLF HZ~ M41 MO0 MOBAO M~E O-L O9- OAUVE OK1 OP~ P-8 P-9 PC. Q38 ROL SDF SSZ Z5R ~HD ~S- 0SF 6I. AACTN AAHOK AFCTW AJOXV NCXOZ RIG AAFTH LCYCR AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c4048-c7ae938eefc1f9fb3c6ff7808f1bc14d5567bceee55fe6561eb381dd1c46c1963 |
| IEDL.DBID | DOA |
| ISSN | 2173-5808 |
| IngestDate | Fri Oct 03 12:51:32 EDT 2025 Sun Sep 28 03:02:46 EDT 2025 Tue Nov 18 20:53:14 EST 2025 Wed Nov 05 20:26:59 EST 2025 Fri Feb 23 02:42:54 EST 2024 Tue Feb 25 20:09:55 EST 2025 Tue Oct 14 19:32:28 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4048-c7ae938eefc1f9fb3c6ff7808f1bc14d5567bceee55fe6561eb381dd1c46c1963 |
| Notes | content type line 23 SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 |
| OpenAccessLink | https://doaj.org/article/1e53e08b0b2849cd9c1b0fb4f9eabf90 |
| PQID | 2550623850 |
| PQPubID | 23479 |
| PageCount | 3 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1e53e08b0b2849cd9c1b0fb4f9eabf90 proquest_miscellaneous_2550623850 crossref_citationtrail_10_1016_j_nrleng_2020_10_008 crossref_primary_10_1016_j_nrleng_2020_10_008 elsevier_sciencedirect_doi_10_1016_j_nrleng_2020_10_008 elsevier_clinicalkeyesjournals_1_s2_0_S2173580821000973 elsevier_clinicalkey_doi_10_1016_j_nrleng_2020_10_008 |
| PublicationCentury | 2000 |
| PublicationDate | 20211001 |
| PublicationDateYYYYMMDD | 2021-10-01 |
| PublicationDate_xml | – month: 10 year: 2021 text: 20211001 day: 01 |
| PublicationDecade | 2020 |
| PublicationTitle | Neurología (Barcelona, English ed. ) |
| PublicationYear | 2021 |
| Publisher | Elsevier España, S.L.U Elsevier España |
| Publisher_xml | – name: Elsevier España, S.L.U – name: Elsevier España |
| References | Ferrari, Diener, Ning, Galic, Cohen, Yang (bib0040) 2019; 394 Ziegeler, May (bib0070) 2020; 60 [Accessed 8 October 2020]. GBD 2016 Neurology Collaborators (bib0075) 2019; 18 Sun, Dodick, Silberstein, Goadsby, Reuter, Ashina (bib0010) 2016; 15 Guerrero Peral, García-Moncó, Oterino Durán, Díaz, Irimia Sieira (bib0080) 2020 Agencia Europea de Medicamentos. Informe de Evaluación Pública Europea. Aimovig. Publicado por primera vez el 8 de Ago de 2018, actualizado el 9 de Sep de 2020 Goadsby, Reuter, Hallström, Broessner, Bonner, Zhang (bib0020) 2017; 377 Santos-Lasaosa, Belvís, Cuadrado, Díaz-Insa, Gago-Veiga, Guerrero-Peral (bib0055) 2019 Deen, Correnti, Kamm, Kelderman, Papetti, Rubio-Beltrán (bib0065) 2017; 18 Tepper, Ashina, Reuter, Brandes, Doležil, Silberstein (bib0015) 2017; 16 Charles, Pozo-Rosich (bib0050) 2019; 394 Dodick, Ashina, Brandes, Kudrow, Lanteri-Minet, Osipova (bib0025) 2018; 38 Holland, Goadsby, Wang, Friedman, Selszer, Aurora (bib0030) 2018; 91 Mulleners, Kim, Lainez, Lanteri-Minet, Pozo Rosich, Wang (bib0035) 2020; 19 Tringali, Navarra (bib0060) 2019; 116 Agencia Española de Medicamentos y Productos Sanitarios (bib0045) 2019 Santos-Lasaosa (10.1016/j.nrleng.2020.10.008_bib0055) 2019 GBD 2016 Neurology Collaborators (10.1016/j.nrleng.2020.10.008_bib0075) 2019; 18 10.1016/j.nrleng.2020.10.008_bib0005 Agencia Española de Medicamentos y Productos Sanitarios (10.1016/j.nrleng.2020.10.008_bib0045) 2019 Tringali (10.1016/j.nrleng.2020.10.008_bib0060) 2019; 116 Mulleners (10.1016/j.nrleng.2020.10.008_bib0035) 2020; 19 Guerrero Peral (10.1016/j.nrleng.2020.10.008_bib0080) 2020 Dodick (10.1016/j.nrleng.2020.10.008_bib0025) 2018; 38 Sun (10.1016/j.nrleng.2020.10.008_bib0010) 2016; 15 Tepper (10.1016/j.nrleng.2020.10.008_bib0015) 2017; 16 Ziegeler (10.1016/j.nrleng.2020.10.008_bib0070) 2020; 60 Charles (10.1016/j.nrleng.2020.10.008_bib0050) 2019; 394 Holland (10.1016/j.nrleng.2020.10.008_bib0030) 2018; 91 Ferrari (10.1016/j.nrleng.2020.10.008_bib0040) 2019; 394 Deen (10.1016/j.nrleng.2020.10.008_bib0065) 2017; 18 Goadsby (10.1016/j.nrleng.2020.10.008_bib0020) 2017; 377 |
| References_xml | – year: 2019 ident: bib0045 article-title: Informe de posicionamiento terapéutico de erenumab (aimovig) en la profilaxis de la migraña, versión 1 – volume: 18 start-page: 96 year: 2017 ident: bib0065 article-title: Blocking CGRP in migraine patients — a review of pros and cons publication-title: J Headache Pain – year: 2020 ident: bib0080 article-title: Migraña crónica publication-title: Manual de práctica clínica en cefaleas. Recomendaciones diagnóstico-terapéuticas de la Sociedad Española de Neurología – volume: 116 start-page: 16 year: 2019 end-page: 21 ident: bib0060 article-title: Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis publication-title: Peptides – volume: 15 start-page: 382 year: 2016 end-page: 390 ident: bib0010 article-title: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet Neurol – year: 2019 ident: bib0055 article-title: Calcitonin gene-related peptide in migraine: from pathophysiology to treatment publication-title: Neurologia – volume: 394 start-page: 1030 year: 2019 end-page: 1040 ident: bib0040 article-title: Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial publication-title: Lancet – volume: 394 start-page: 1765 year: 2019 end-page: 1774 ident: bib0050 article-title: Targeting calcitonin gene-related peptide: a new era in migraine therapy publication-title: Lancet – reference: Agencia Europea de Medicamentos. Informe de Evaluación Pública Europea. Aimovig. Publicado por primera vez el 8 de Ago de 2018, actualizado el 9 de Sep de 2020, – volume: 38 start-page: 1026 year: 2018 end-page: 1037 ident: bib0025 article-title: ARISE: a phase 3 randomized trial of erenumab for episodic migraine publication-title: Cephalalgia – volume: 60 start-page: 469 year: 2020 end-page: 470 ident: bib0070 article-title: Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class publication-title: Headache – reference: [Accessed 8 October 2020]. – volume: 91 start-page: e2211 year: 2018 end-page: e2221 ident: bib0030 article-title: Galcanezumab in chronic migraine. The randomized, double-blind, placebo-controlled REGAIN study publication-title: Neurology – volume: 19 start-page: 814 year: 2020 end-page: 825 ident: bib0035 article-title: Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial publication-title: Lancet Neurol – volume: 18 start-page: 459 year: 2019 end-page: 480 ident: bib0075 article-title: Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 publication-title: Lancet Neurol – volume: 377 start-page: 2123 year: 2017 end-page: 2132 ident: bib0020 article-title: A Controlled Trial of Erenumab for Episodic Migraine publication-title: N Engl J Med – volume: 16 start-page: 425 year: 2017 end-page: 434 ident: bib0015 article-title: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial publication-title: Lancet Neurol – year: 2019 ident: 10.1016/j.nrleng.2020.10.008_bib0045 – ident: 10.1016/j.nrleng.2020.10.008_bib0005 – volume: 394 start-page: 1765 issue: November (10210) year: 2019 ident: 10.1016/j.nrleng.2020.10.008_bib0050 article-title: Targeting calcitonin gene-related peptide: a new era in migraine therapy publication-title: Lancet doi: 10.1016/S0140-6736(19)32504-8 – volume: 91 start-page: e2211 year: 2018 ident: 10.1016/j.nrleng.2020.10.008_bib0030 article-title: Galcanezumab in chronic migraine. The randomized, double-blind, placebo-controlled REGAIN study publication-title: Neurology – volume: 18 start-page: 96 issue: September year: 2017 ident: 10.1016/j.nrleng.2020.10.008_bib0065 article-title: Blocking CGRP in migraine patients — a review of pros and cons publication-title: J Headache Pain doi: 10.1186/s10194-017-0807-1 – volume: 394 start-page: 1030 issue: September year: 2019 ident: 10.1016/j.nrleng.2020.10.008_bib0040 article-title: Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial publication-title: Lancet doi: 10.1016/S0140-6736(19)31946-4 – volume: 18 start-page: 459 issue: May year: 2019 ident: 10.1016/j.nrleng.2020.10.008_bib0075 article-title: Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 publication-title: Lancet Neurol – volume: 60 start-page: 469 issue: February year: 2020 ident: 10.1016/j.nrleng.2020.10.008_bib0070 article-title: Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class publication-title: Headache doi: 10.1111/head.13729 – volume: 16 start-page: 425 issue: June year: 2017 ident: 10.1016/j.nrleng.2020.10.008_bib0015 article-title: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(17)30083-2 – issue: July year: 2019 ident: 10.1016/j.nrleng.2020.10.008_bib0055 article-title: Calcitonin gene-related peptide in migraine: from pathophysiology to treatment publication-title: Neurologia – volume: 15 start-page: 382 issue: April year: 2016 ident: 10.1016/j.nrleng.2020.10.008_bib0010 article-title: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(16)00019-3 – volume: 38 start-page: 1026 issue: May year: 2018 ident: 10.1016/j.nrleng.2020.10.008_bib0025 article-title: ARISE: a phase 3 randomized trial of erenumab for episodic migraine publication-title: Cephalalgia doi: 10.1177/0333102418759786 – volume: 116 start-page: 16 issue: June year: 2019 ident: 10.1016/j.nrleng.2020.10.008_bib0060 article-title: Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis publication-title: Peptides doi: 10.1016/j.peptides.2019.04.012 – year: 2020 ident: 10.1016/j.nrleng.2020.10.008_bib0080 article-title: Migraña crónica – volume: 377 start-page: 2123 issue: November year: 2017 ident: 10.1016/j.nrleng.2020.10.008_bib0020 article-title: A Controlled Trial of Erenumab for Episodic Migraine publication-title: N Engl J Med doi: 10.1056/NEJMoa1705848 – volume: 19 start-page: 814 year: 2020 ident: 10.1016/j.nrleng.2020.10.008_bib0035 article-title: Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(20)30279-9 |
| SSID | ssj0000651802 |
| Score | 2.1586673 |
| SourceID | doaj proquest crossref elsevier |
| SourceType | Open Website Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 638 |
| SubjectTerms | Internal Medicine Neurology |
| Title | Failure of monoclonal antibodies against CGRP or its receptor does not imply lack of efficacy of other drugs from the same class |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2173580821000973 https://www.clinicalkey.es/playcontent/1-s2.0-S2173580821000973 https://dx.doi.org/10.1016/j.nrleng.2020.10.008 https://www.proquest.com/docview/2550623850 https://doaj.org/article/1e53e08b0b2849cd9c1b0fb4f9eabf90 |
| Volume | 36 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Open Access Full Text customDbUrl: eissn: 2173-5808 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000651802 issn: 2173-5808 databaseCode: DOA dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2173-5808 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000651802 issn: 2173-5808 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA66iHgRnzirLhG8NqYfmSRHXXb04C6LL-YWknRlaZntHrpnhL2IP92qfiyzIowHL8NMSNJDVaXqq049GHvthfNQ5iIJqUcHRUWXeAPkpfgIaJ616m_wv31UZ2d6uTTnO62-KCZsKA88EO5NCjIHob3wqEhNKA1uKqIvogHno-m9dUQ9O87UoIMllTajznKpyhOphZ7y5vrgrrqlPiXoHmY0RDVOb9ilvnz_DfP0h6Lurc_iAbs_wkb-dvi7D9ktqB-xu6fjxfhj9mvhKgow503kKFhNWBHC5ki2yjcUKMjdhasQCvLj95_OedPyatNx1HawRqeblw3OqJsNry7XqytOL_VoJ6D6Ei5c0fc-U4uX7fai45STwvE379wl8EAA_An7ujj5cvwhGZsrJKHAU5sE5cDkGiCGNJro8zCPUSGdYupDWpRSzpVHCwpSRkDQl6LXjdi2TEMxD3Rsn7KDuqnhGeMGIYBR0kfldOEg6lJDJoBeKpXk381YPpHWhrHyODXAWNkpxOy7HRhiiSE0igyZseR61XqovLFn_jvi2vVcqpvdD6A02VGa7D5pmjE58dxOqamoTHGjas_D1d_WQTdqhM6mtsussJ9JHkkcs7TPocl3V46gZwAz__DMV5NQWtQJdNHjami2nUU3USCs1VIc_g-iPGf3Mork6UMYX7CDTbuFl-xO-LGpuvaI3VZLfdQfP_w8_XnyGxSDNg8 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Failure+of+monoclonal+antibodies+against+CGRP+or+its+receptor+does+not+imply+lack+of+efficacy+of+other+drugs+from+the+same+class&rft.jtitle=Neurolog%C3%ADa+%28Barcelona%2C+English+ed.+%29&rft.au=J.+Porta-Etessam&rft.au=N.+Gonz%C3%A1lez-Garc%C3%ADa&rft.au=%C3%81.L.+Guerrero&rft.au=D.+Garc%C3%ADa-Azor%C3%ADn&rft.date=2021-10-01&rft.pub=Elsevier+Espa%C3%B1a&rft.issn=2173-5808&rft.eissn=2173-5808&rft.volume=36&rft.issue=8&rft.spage=638&rft.epage=640&rft_id=info:doi/10.1016%2Fj.nrleng.2020.10.008&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1e53e08b0b2849cd9c1b0fb4f9eabf90 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F21735808%2FS2173580820X00186%2Fcov150h.gif |